

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2011; month=4; day=11; hr=13; min=31; sec=23; ms=954;]

=====

Application No: 10591732 Version No: 1.0

Input Set:

Output Set:

Started: 2011-04-04 12:19:51.518
Finished: 2011-04-04 12:19:52.085
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 567 ms
Total Warnings: 5
Total Errors: 0
No. of SeqIDs Defined: 5
Actual SeqID Count: 5

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)

SEQUENCE LISTING

<110> DAKE, MICHAEL D.
WAUGH, JACOB M.

<120> COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND
TRANSDERMAL DELIVERY OF BOTULINUM TOXINS

<130> 13720-105071US2

<140> 10591732

<141> 2011-04-04

<150> PCT/US05/07524

<151> 2005-03-03

<150> 60/550,015

<151> 2004-03-03

<160> 5

<170> PatentIn Ver. 3.5

<210> 1

<211> 45

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> misc_feature

<222> (1)..(20)

<223> This region may encompass 0 to 20 "Gly" residues

<220>

<221> misc_feature

<222> (21)..(45)

<223> This region may encompass 5, 7, 9, 11, 13, 15,
17, 19, 21, 23 or 25 "Arg" residues

<220>

<223> see specification as filed for detailed description of
substitutions and preferred embodiments

<400> 1

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
20 25 30

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
35 40 45

<210> 2
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> misc_feature
<222> (1)..(20)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<221> misc_feature
<222> (32)..(51)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<223> see specification as filed for detailed description of
substitutions and preferred embodiments

<400> 2
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
35 40 45

Gly Gly Gly
50

<210> 3
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>

Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
35 40 45

Gly

<210> 5

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 5

Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg
1 5 10